Working... Menu

Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00005578
Recruitment Status : Completed
First Posted : May 26, 2004
Last Update Posted : July 24, 2014
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : October 2004
  Actual Study Completion Date : June 2008
Publications of Results:
Constine LS, Marcus R, Chauvenet A, et al.: Patterns of failure after response-based, dose-dense therapy for intermediate/high risk pediatric Hodgkin's disease (POG 9425). [Abstract] Int J Radiat Oncol Biol Phys 63 (Suppl 1): A-37, S21, 2005.
Schwartz CL, Constine LS, London W, et al.: POG 9425: response-based, intensively timed therapy for intermediate/high stage (IS/HS) pediatric Hodgkin's disease. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1555, 2002.

Other Publications:
Schwartz CL, Tebbi CK, Constine LS: Response based therapy for pediatric Hodgkin's disease (HD): Pediatric Oncology Group (POG) protocols 9425/9426. [Abstract] Med Pediatr Oncol 37 (3): A-P219, 263, 2001.